Diem H, Fateh-Moghadam A, Lamerz R
Institut für Klinische Chemie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
Clin Investig. 1993 Nov;71(11):918-23. doi: 10.1007/BF00185604.
Serum beta 2-microglobulin, serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only albumin, serum beta 2-microglobulin and serum thymidine kinase added further prognostic information. When tested for efficiency in recognizing patients with poor (average survival time < 1 year) and good (average survival time > 5 years) prognosis, serum beta 2-microglobulin was best (80%), followed by total urinary protein (78%), hemoglobin (76%), and albumin (75%).
在一组明确诊断的多发性骨髓瘤患者（n = 207）中，研究了血清β2-微球蛋白、血清胸苷激酶及常用预后参数的预后价值。多变量分析显示血红蛋白是预后价值最强的参数。只有白蛋白、血清β2-微球蛋白和血清胸苷激酶可提供更多的预后信息。在识别预后差（平均生存时间<1年）和预后好（平均生存时间>5年）的患者时进行效能测试，血清β2-微球蛋白表现最佳（80%），其次是总尿蛋白（78%）、血红蛋白（76%）和白蛋白（75%）。
